Catalog #SIM0081
InVivoSIM bispecific anti-human EGFR x MET (Amivantamab Biosimilar)
Clone
Amivantamab
Isotype
Human IgG1, κ
Product Description
This biosimilar antibody uses the same variable regions as the therapeutic antibody Amivantamab, making it ideal for research use. Amivantamab is a fully human IgG1 bispecific monoclonal antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and c‑Met (MET). By binding to these receptors, it blocks ligand binding and promotes receptor internalization and degradation. Clinically, Amivantamab is approved for the treatment of adults with non–small-cell lung cancer (NSCLC) bearing EGFR exon 20 insertion mutations, especially following disease progression after platinum-based chemotherapy. This Amivantamab biosimilar is intended only for research use, and is well suited for studying mechanisms of receptor blockade, receptor downmodulation, and immune effector activation in EGFR- and MET-driven tumor models.
Specifications
| Isotype | Human IgG1, κ |
|---|---|
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Reported Applications |
in vivo functional assays in vitro functional assays |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |